Search
Novel basis for chemoresistance in AML: DNMT3A R882 mutations promote chemoresistance and residual disease through impaired DNA damage sensing
Although most acute myeloid leukemia (AML) patients initially respond to chemotherapy, the majority subsequently relapses and succumbs to refractory disease. Residual leukemic cells that survived chemotherapy may persist over time and later cause the disease to come back.
Read morePractical information
When do the meetings take place?
CRTH 2025 timeline is as follows:
Workshop 1: Tuesday, February 4 – Saturday, February 8, 2025
EHA2025 Congress: Thursday, June 12 – Sunday, June 15, 2025
> CRTH Congress session date TBC.
SWG Educational Activities
EHA-SWG SCIENTIFIC MEETING ON INTEGRATED CELL TRACKING IN ONCOHEMATOLOGY: DIAGNOSIS, TARGETED THERAPY AND RESIDUAL DISEASE
November 10-11, 2022 | Bordeaux, France
Meeting Chairs:
MC Béné, Nantes University
G Zini, Università Cattolica S.
A Special Coach for the Cantera 2024
A unique tutorial for young hematologists, co-sponsored by the EHA Lymphoma Group and the Fondazione Italiana Linfomi. DatesMay 14 to May 17, 2024. LocationLecce, Italy. TopicHow the utilization of cellular therapy strategies looks for lymphomas in 2024.
Read moreAbstract submission
Submit your abstract for a poster presentation here
Abstract procedurePlease note that the submission of an abstract constitutes a formal commitment by the presenting author to present the abstract (if accepted) orally or as a poster in the session at the…
SWG Educational Activities
EHA-SWG meetingsAn EMSCO meeting was held in October 2023 (Nice, France).
Read more